Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Journal
Age
Showing 1 to 12 of 284 entries
Sorted by: Best Match Show Resources per page
Studies on improved corneal permeability to bunazosin.

Journal of pharmacobio-dynamics

Kato A, Iwata S.
PMID: 2902207
J Pharmacobiodyn. 1988 May;11(5):330-4. doi: 10.1248/bpb1978.11.330.

Various factors influencing corneal permeability to bunazosin were investigated. The permeability of the cornea to bunazosin increased with increasing pH, either in the presence or absence of caprylic acid; the permeability to bunazosin and the partition of bunazosin were...

Cite
Kato A, Iwata S. Studies on improved corneal permeability to bunazosin. J Pharmacobiodyn. 1988;11(5):330-4doi: 10.1248/bpb1978.11.330.
Kato, A., & Iwata, S. (1988). Studies on improved corneal permeability to bunazosin. Journal of pharmacobio-dynamics, 11(5), 330-4. https://doi.org/10.1248/bpb1978.11.330
Kato, A, and Iwata, S. "Studies on improved corneal permeability to bunazosin." Journal of pharmacobio-dynamics vol. 11,5 (1988): 330-4. doi: https://doi.org/10.1248/bpb1978.11.330
Kato A, Iwata S. Studies on improved corneal permeability to bunazosin. J Pharmacobiodyn. 1988 May;11(5):330-4. doi: 10.1248/bpb1978.11.330. PMID: 2902207.
Copy Download .nbib Format: NLM
A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin.

Xenobiotica; the fate of foreign compounds in biological systems

Pierce DM.
PMID: 1981634
Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634.

1. The alpha 1-adrenoceptor antagonist indoramin is rapidly and extensively absorbed after oral administration, but with only low to moderate bioavailability (8-24% median) from the tablet (Baratol). Although plasma protein binding is high (72-86%), the drug is widely distributed...

Cite
Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990;20(12):1357-67doi: 10.3109/00498259009046634.
Pierce, D. M. (1990). A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica; the fate of foreign compounds in biological systems, 20(12), 1357-67. https://doi.org/10.3109/00498259009046634
Pierce, D M. "A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin." Xenobiotica; the fate of foreign compounds in biological systems vol. 20,12 (1990): 1357-67. doi: https://doi.org/10.3109/00498259009046634
Pierce DM. A review of the clinical pharmacokinetics and metabolism of the alpha 1-adrenoceptor antagonist indoramin. Xenobiotica. 1990 Dec;20(12):1357-67. doi: 10.3109/00498259009046634. PMID: 1981634.
Copy Download .nbib Format: NLM
New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance.

American heart journal

Cubeddu LX.
PMID: 2899387
Am Heart J. 1988 Jul;116(1):133-62. doi: 10.1016/0002-8703(88)90261-x.

The pharmacology, clinical efficacy and safety of new alpha-adrenergic receptor antagonists for the treatment of hypertension was reviewed (Table XIV). Although all these agents block alpha 1 receptors, some of them have additional effects on histamine, serotonin, dopamine, and...

Cite
Cubeddu LX. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Am Heart J. 1988;116(1):133-62doi: 10.1016/0002-8703(88)90261-x.
Cubeddu, L. X. (1988). New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. American heart journal, 116(1), 133-62. https://doi.org/10.1016/0002-8703(88)90261-x
Cubeddu, L X. "New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance." American heart journal vol. 116,1 (1988): 133-62. doi: https://doi.org/10.1016/0002-8703(88)90261-x
Cubeddu LX. New alpha 1-adrenergic receptor antagonists for the treatment of hypertension: role of vascular alpha receptors in the control of peripheral resistance. Am Heart J. 1988 Jul;116(1):133-62. doi: 10.1016/0002-8703(88)90261-x. PMID: 2899387.
Copy Download .nbib Format: NLM
Quantitative in vitro and ex vivo autoradiography of the alpha 2-adrenoceptor antagonist [3H]atipamezole.

European journal of pharmacology

Biegon A, Mathis CA, Budinger TF.
PMID: 1360406
Eur J Pharmacol. 1992 Nov 24;224(1):27-38. doi: 10.1016/0014-2999(92)94814-c.

Atipamezole is an alpha-adrenoceptor antagonist with high affinity and selectivity for the alpha 2-receptor. In vitro autoradiography of [3H]atipamezole on rat and human brain sections revealed a pattern virtually identical to the one observed using 3H-labeled antagonists such as...

Cite
Biegon A, Mathis CA, Budinger TF. Quantitative in vitro and ex vivo autoradiography of the alpha 2-adrenoceptor antagonist [3H]atipamezole. Eur J Pharmacol. 1992;224(1):27-38doi: 10.1016/0014-2999(92)94814-c.
Biegon, A., Mathis, C. A., & Budinger, T. F. (1992). Quantitative in vitro and ex vivo autoradiography of the alpha 2-adrenoceptor antagonist [3H]atipamezole. European journal of pharmacology, 224(1), 27-38. https://doi.org/10.1016/0014-2999(92)94814-c
Biegon, A, et al. "Quantitative in vitro and ex vivo autoradiography of the alpha 2-adrenoceptor antagonist [3H]atipamezole." European journal of pharmacology vol. 224,1 (1992): 27-38. doi: https://doi.org/10.1016/0014-2999(92)94814-c
Biegon A, Mathis CA, Budinger TF. Quantitative in vitro and ex vivo autoradiography of the alpha 2-adrenoceptor antagonist [3H]atipamezole. Eur J Pharmacol. 1992 Nov 24;224(1):27-38. doi: 10.1016/0014-2999(92)94814-c. PMID: 1360406.
Copy Download .nbib Format: NLM
The use of alpha 1 adrenergic blocking agents for hypertension.

American pharmacy

Limon L.
PMID: 1973330
Am Pharm. 1990 Jun;(6):54-8. doi: 10.1016/s0160-3450(15)31458-6.

No abstract available.

Cite
Limon L. The use of alpha 1 adrenergic blocking agents for hypertension. Am Pharm. 1990;(6):54-8doi: 10.1016/s0160-3450(15)31458-6.
Limon, L. (1990). The use of alpha 1 adrenergic blocking agents for hypertension. American pharmacy, (6), 54-8. https://doi.org/10.1016/s0160-3450(15)31458-6
Limon, L. "The use of alpha 1 adrenergic blocking agents for hypertension." American pharmacy vol. ,6 (1990): 54-8. doi: https://doi.org/10.1016/s0160-3450(15)31458-6
Limon L. The use of alpha 1 adrenergic blocking agents for hypertension. Am Pharm. 1990 Jun;(6):54-8. doi: 10.1016/s0160-3450(15)31458-6. PMID: 1973330.
Copy Download .nbib Format: NLM
Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin.

Xenobiotica; the fate of foreign compounds in biological systems

Meredith PA, Elliott HL, Kelman AW, Vincent J, Reid JL.
PMID: 2895548
Xenobiotica. 1988 Jan;18(1):123-9. doi: 10.3109/00498258809055143.

1. The pharmacokinetic and pharmacodynamic profiles of intravenous and oral doxazosin were investigated in 6 normotensive volunteers. 2. The pharmacokinetics of i.v. and oral doxazosin were fitted simultaneously and independently. The parameters derived were in good agreement with a...

Cite
Meredith PA, Elliott HL, Kelman AW, et al. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988;18(1):123-9doi: 10.3109/00498258809055143.
Meredith, P. A., Elliott, H. L., Kelman, A. W., Vincent, J., & Reid, J. L. (1988). Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica; the fate of foreign compounds in biological systems, 18(1), 123-9. https://doi.org/10.3109/00498258809055143
Meredith, P A, et al. "Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin." Xenobiotica; the fate of foreign compounds in biological systems vol. 18,1 (1988): 123-9. doi: https://doi.org/10.3109/00498258809055143
Meredith PA, Elliott HL, Kelman AW, Vincent J, Reid JL. Pharmacokinetic and pharmacodynamic modelling of the alpha adrenoceptor antagonist doxazosin. Xenobiotica. 1988 Jan;18(1):123-9. doi: 10.3109/00498258809055143. PMID: 2895548.
Copy Download .nbib Format: NLM
[Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension].

Der Internist

Dominiak P.
PMID: 8103510
Internist (Berl). 1993 Jul;34(7):682-7.

No abstract available.

Cite
Dominiak P. Doxazosin. Ein postsynaptischer alpha 1-Adrenozeptorenblocker in der Hochdrucktherapie. [Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension]. Internist (Berl). 1993;34(7):682-7
Dominiak, P. (1993). Doxazosin. Ein postsynaptischer alpha 1-Adrenozeptorenblocker in der Hochdrucktherapie. [Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension]. Der Internist, 34(7), 682-7.
Dominiak, P. "Doxazosin. Ein postsynaptischer alpha 1-Adrenozeptorenblocker in der Hochdrucktherapie." [Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension]. Der Internist vol. 34,7 (1993): 682-7.
Dominiak P. Doxazosin. Ein postsynaptischer alpha 1-Adrenozeptorenblocker in der Hochdrucktherapie. [Doxazosin. A postsynaptic alpha 1-adrenergic receptor blocker in therapy of hypertension]. Internist (Berl). 1993 Jul;34(7):682-7. German. PMID: 8103510.
Copy Download .nbib Format: NLM
[Proxodolol pharmacokinetics in rats and rabbits].

Eksperimental'naia i klinicheskaia farmakologiia

Rumiantsev DO, Piotrovskiĭ VK, Metelitsa VI, Golovanova IV, Ermachenkov IA, Gus'kova TA.
PMID: 7914117
Eksp Klin Farmakol. 1994 May-Jun;57(3):36-8.

In non-inbred rats, the pharmacokinetics of proxodolol was studied after its intravenous administration in a dose of 1 mg/kg or oral use in a dose of 50 mg/kg as 1% aqueous solution, in Chinchilla rabbits, it was examined after...

Cite
Rumiantsev DO, Piotrovskiĭ VK, Metelitsa VI, et al. Farmakokinetika proksodolola u krys i krolikov. [Proxodolol pharmacokinetics in rats and rabbits]. Eksp Klin Farmakol. 1994;57(3):36-8
Rumiantsev, D. O., Piotrovskiĭ, V. K., Metelitsa, V. I., Golovanova, I. V., Ermachenkov, I. A., & Gus'kova, T. A. (1994). Farmakokinetika proksodolola u krys i krolikov. [Proxodolol pharmacokinetics in rats and rabbits]. Eksperimental'naia i klinicheskaia farmakologiia, 57(3), 36-8.
Rumiantsev, D O, et al. "Farmakokinetika proksodolola u krys i krolikov." [Proxodolol pharmacokinetics in rats and rabbits]. Eksperimental'naia i klinicheskaia farmakologiia vol. 57,3 (1994): 36-8.
Rumiantsev DO, Piotrovskiĭ VK, Metelitsa VI, Golovanova IV, Ermachenkov IA, Gus'kova TA. Farmakokinetika proksodolola u krys i krolikov. [Proxodolol pharmacokinetics in rats and rabbits]. Eksp Klin Farmakol. 1994 May-Jun;57(3):36-8. Russian. PMID: 7914117.
Copy Download .nbib Format: NLM
Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action.

Investigative ophthalmology & visual science

Mizuno K, Koide T, Yoshimura M, Araie M.
PMID: 11222528
Invest Ophthalmol Vis Sci. 2001 Mar;42(3):688-94.

PURPOSE: To investigate the effect of nipradilol, an alpha(1),beta-blocker with a nitric oxide donative action, on N:-methyl-D-aspartate (NMDA)-induced retinal damage in rats and to determine whether topically instilled nipradilol penetrates the ipsilateral posterior retina-choroid at pharmacologically active concentrations in...

Cite
Mizuno K, Koide T, Yoshimura M, et al. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci. 2001;42(3):688-94
Mizuno, K., Koide, T., Yoshimura, M., & Araie, M. (2001). Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Investigative ophthalmology & visual science, 42(3), 688-94.
Mizuno, K, et al. "Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action." Investigative ophthalmology & visual science vol. 42,3 (2001): 688-94.
Mizuno K, Koide T, Yoshimura M, Araie M. Neuroprotective effect and intraocular penetration of nipradilol, a beta-blocker with nitric oxide donative action. Invest Ophthalmol Vis Sci. 2001 Mar;42(3):688-94. PMID: 11222528.
Copy Download .nbib Format: NLM
The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.

European journal of clinical pharmacology

Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH.
PMID: 10424319
Eur J Clin Pharmacol. 1999 Jun;55(4):269-77. doi: 10.1007/s002280050628.

INTRODUCTION: Carvedilol, a chiral compound possessing nonselective beta- and alpha1-blocking activity, is used for the treatment of hypertension and congestive heart failure (CHF). The enantiomers of carvedilol exhibit similar alpha1-blocking activity; only S-carvedilol possesses beta-blocking activity. Carvedilol is primarily...

Cite
Gehr TW, Tenero DM, Boyle DA, et al. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999;55(4):269-77doi: 10.1007/s002280050628.
Gehr, T. W., Tenero, D. M., Boyle, D. A., Qian, Y., Sica, D. A., & Shusterman, N. H. (1999). The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. European journal of clinical pharmacology, 55(4), 269-77. https://doi.org/10.1007/s002280050628
Gehr, T W, et al. "The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency." European journal of clinical pharmacology vol. 55,4 (1999): 269-77. doi: https://doi.org/10.1007/s002280050628
Gehr TW, Tenero DM, Boyle DA, Qian Y, Sica DA, Shusterman NH. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol. 1999 Jun;55(4):269-77. doi: 10.1007/s002280050628. PMID: 10424319.
Copy Download .nbib Format: NLM
Quantitation of tamsulosin in human plasma by liquid chromatography-electrospray ionization mass spectrometry.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Din L, Li L, Tao P, Yang J, Zhang Z.
PMID: 11863298
J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 05;767(1):75-81. doi: 10.1016/s0378-4347(01)00546-1.

A highly sensitive method for quantitation of tamsulosin in human plasma using 1-(2,6-dimethyl-3-hydroxylphenoxy)-2-(3,4-methoxyphenylethylamino)-propane hydrochloride as the internal standard (I.S.) was established using liquid chromatography-electrospray ionization-mass spectrometry (LC-ESI-MS). After alkalization with saturated sodium bicarbonate, plasma were extracted by ethyl acetate...

Cite
Din L, Li L, Tao P, et al. Quantitation of tamsulosin in human plasma by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;767(1):75-81doi: 10.1016/s0378-4347(01)00546-1.
Din, L., Li, L., Tao, P., Yang, J., & Zhang, Z. (2002). Quantitation of tamsulosin in human plasma by liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 767(1), 75-81. https://doi.org/10.1016/s0378-4347(01)00546-1
Din, Li, et al. "Quantitation of tamsulosin in human plasma by liquid chromatography-electrospray ionization mass spectrometry." Journal of chromatography. B, Analytical technologies in the biomedical and life sciences vol. 767,1 (2002): 75-81. doi: https://doi.org/10.1016/s0378-4347(01)00546-1
Din L, Li L, Tao P, Yang J, Zhang Z. Quantitation of tamsulosin in human plasma by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002 Feb 05;767(1):75-81. doi: 10.1016/s0378-4347(01)00546-1. PMID: 11863298.
Copy Download .nbib Format: NLM
Iontophoretic transdermal delivery of salbutamol: methyl-orange ion-pair.

Die Pharmazie

Sant VP, Khopade AJ, Jain NK.
PMID: 9631502
Pharmazie. 1998 May;53(5):334-6.

The influence of pulsed current duty cycle, addition of electrically neutral species and pH on iontophoretic transdermal delivery of an organic ion-pair salbutamol:methyl orange through excised rabbit abdominal skin is described. It was compared with salbutamol sulphate and salbutamol:sulphate...

Cite
Sant VP, Khopade AJ, Jain NK. Iontophoretic transdermal delivery of salbutamol: methyl-orange ion-pair. Pharmazie. 1998;53(5):334-6
Sant, V. P., Khopade, A. J., & Jain, N. K. (1998). Iontophoretic transdermal delivery of salbutamol: methyl-orange ion-pair. Die Pharmazie, 53(5), 334-6.
Sant, V P, et al. "Iontophoretic transdermal delivery of salbutamol: methyl-orange ion-pair." Die Pharmazie vol. 53,5 (1998): 334-6.
Sant VP, Khopade AJ, Jain NK. Iontophoretic transdermal delivery of salbutamol: methyl-orange ion-pair. Pharmazie. 1998 May;53(5):334-6. PMID: 9631502.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 284 entries